Wanhuida Intellectual Property

Wu Xiaoping of Wanhuida Intellectual Property says the methodology often applied in assessing inventiveness in pharmaceutical patent litigation cases is set to be used in re-examination and invalidation proceedings after the CNIPA makes an invalidation decision a quasi-precedent

Wu Xiaohui of Wanhuida Intellectual Property explains why a recent decision on inventiveness assessments of co-solvent compound crystals heralds a significant shift in focus by the CNIPA, with implications for pharmaceutical patent strategies

A ruling on the inventiveness of a compound patent for a prostate cancer therapeutic could help create uniform jurisprudence regarding the examination of pharmaceutical patents, says Guan Yue of Wanhuida Intellectual Property

Rui Wang of Wanhuida Intellectual Property says inventors should focus on improving AI systems’ transparency and predictability to enhance their patentability and identifies a challenge resulting from the interdisciplinary techniques involved in examination

Wu Xiaohui of Wanhuida Intellectual Property explains the significance of a ruling by the Supreme People’s Court after the rejection of an invention patent application

Feng Zheng and Xiaoyang Yang of Wanhuida Intellectual Property provide an insight into current Chinese practice concerning trade secrets and non-compete clauses/agreements based on the legal framework and recent court decisions